None of the observations identified a specific issue regarding the performance of any particular product and all products continue to be manufactured by the facility. Zimmer Biomet stands behind the safety of the products manufactured at the Warsaw North Campus." The release continues, "The company notes that this re-inspection occurred as it continues to execute against its approximately two-year quality remediation plan at the Warsaw North Campus. Zimmer Biomet believes that considerable progress has been made over the past year, but more work remains to be completed. The company takes the FDA's observations very seriously and, as part of the ongoing two-year remediation effort, continues to work diligently with independent consultants to address both existing and new Form 483 observations."